Category - AstraZeneca
-
AstraZeneca held talks on $400B megadeal, source says
-
AstraZeneca held talks on $400B megadeal, source says
-
AstraZeneca held talks on $400B megadeal, source says
-
AstraZeneca held talks on $400B megadeal, source says
-
AstraZeneca held talks on $400B megadeal, source says
-
AstraZeneca held talks on $400B megadeal, source says
-
AstraZeneca held talks on $400B megadeal, source says
-
AstraZeneca held talks on $400B megadeal, source says
-
AstraZeneca held talks on $400B megadeal, source says
-
AstraZeneca held talks on $400B megadeal, source says
-
Bad reaction
-
AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm
-
Bad reaction
-
AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger
-
AstraZeneca held talks on $400B megadeal, source says
-
UK’s AstraZeneca eyeing $400b merger, report says
-
AstraZeneca held talks on $400B megadeal, source says
-
‘Astra’ bid
-
‘Astra’ bid
-
AstraZeneca boss urges western drugmakers to move at ‘Chinese speed’
-
DATELINE | THIS WEEK
-
Attorney General Ken Paxton Secures Nearly $34 Million in Settlement Agreement with Big Pharma Company AstraZeneca for Giving Illegal Kickbacks to Providers to Prescribe Its Drugs to Texans
-
Justices spurn drug firms’ appeal of cost negotiation program
-
Justices spurn drug firms’ appeal of cost negotiation program
-
Justices reject pharma’s push to block drug price cuts
-
AstraZeneca makes surprise U-turn with £300m pharma investment in UK
-
AstraZeneca to invest $405 million in Britain
-
AstraZeneca will invest $405 million in Britain
-
AstraZeneca to invest $405 million in Britain
-
AstraZeneca to invest $405 million in Britain
-
AstraZeneca to acquire Modella AI to speed drug research
-
AstraZeneca to acquire Modella AI to speed drug research
-
AstraZeneca lauds nation for rare disease control
-
AstraZeneca seals U.S. medicine deal
-
AstraZeneca seals U.S. medicine deal
-
In July, AstraZeneca announced a sprawling
$50 billion investment plan for the U.S. market and in late September said it would do a full U.S. listing of its shares alongside its current London listing.
-
Drugmaker AstraZeneca seals U.S. medicine deal
-
AstraZeneca seals U.S. medicine deal